Complete sentinel cohort enrollment and initiate expansion cohort of the BEACON trial
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 9 Jan 2023
- Due
- 31 Dec 2023
- Checked
- 2 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Complete sentinel cohort enrollment and initiate expansion cohort of BEACON in 2023”
What we found
Evidence strength A What the grades mean
The company did not complete the sentinel cohort enrollment or initiate the expansion cohort of the BEACON trial in 2023, pushing these milestones to the first half of 2024.
-
A Beam Therapeutics Inc. 10-K filed 2024-02-27
“We expect to dose the remaining two patients in the sentinel cohort and initiate dosing in patients in the expansion cohort of the BEACON trial in the first half of 2024” ✓ confirmed on the page
-
A Beam Therapeutics Inc. 10-Q filed 2024-05-07
“In May 2024, we announced that the three patients in the sentinel cohort of the BEACON trial have each been dosed and successfully achieved engraftment. Following engraftment of the third patient, we initiated the expansion phase” ✓ confirmed on the page
Market reaction: the shares moved +9.9% against the S&P 500 over the three sessions around the disclosure (26 Feb 2024 to 29 Feb 2024). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- BEACON trial cohorts
- In the company’s control
- High
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: disagreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and read it as “Late”, so a person decides.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-BEAM-003225 · Corrections policy